跳轉至內容
Merck
全部照片(1)

重要文件

B6309

Sigma-Aldrich

(R)-布他前列素

≥98% (HPLC)

同義詞:

(1R,2R,3R)-3-羟基-2-[(1E,4R)-4-羟基-4-(1-丙基环丁基)-1-丁烯基]-5-氧代环戊烷庚酸甲酯

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C24H40O5
CAS號碼:
分子量::
408.57
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

oil

顏色

light yellow

溶解度

DMSO: freely soluble
ethanol: freely soluble

起源

Bayer

儲存溫度

−20°C

SMILES 字串

CCCC1(CCC1)[C@H](O)C\C=C\[C@H]2[C@H](O)CC(=O)[C@@H]2CCCCCCC(=O)OC

InChI

1S/C24H40O5/c1-3-14-24(15-9-16-24)22(27)12-8-11-19-18(20(25)17-21(19)26)10-6-4-5-7-13-23(28)29-2/h8,11,18-19,21-22,26-27H,3-7,9-10,12-17H2,1-2H3/b11-8+/t18-,19-,21-,22-/m1/s1

InChI 密鑰

XRISENIKJUKIHD-LHQZMKCDSA-N

應用

R)-布他前列素已被用作前列腺素受体(EP)特异性激动剂,用于研究其对MCF7细胞中蛋白激酶A(PKA)调节亚基的作用。它可用作在马丁达比(Madin-Darby)狗肾和小鼠皮质集合管(mpkCCD14)细胞的EP2激动剂。它也可用作人胚肺成纤维细胞(HFL-1)的EP2激动剂,用于测试其对血管内皮生长因子(VEGF)生成的影响。

生化/生理作用

布他前列素包含羟基-环戊酮环和ω-链。它在谷氨酸盐N-甲基-D-天冬氨酸受体毒性中提供保护作用。在青光眼滤过手术后,布他前列素可抑制结膜纤维化并降低眼内压。它还通过减少结膜下瘢痕Tenons′成纤维细胞而促进伤口愈合。布他前列素在肺纤维化中起保护作用,并有助于防止阿尔茨海默氏′病中淀粉样蛋白β(Aβ)肽的聚集。
(R)-布他前列素是一种选择性 EP 2 前列腺素受体激动剂。

特點和優勢

该化合物由Bayer开发。要浏览其他药物开发化合物和批准的药物/候选药物列表,单击此处

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Terence Peters et al.
The Journal of pharmacology and experimental therapeutics, 335(2), 424-433 (2010-08-07)
Protease-activated receptors (PARs) are widely expressed throughout the respiratory tract, and PAR(2) has been investigated as a potential drug target for inflammatory airway diseases. The primary focus of this study was to determine the extent to which PAR(2)-activating peptides modulate
Boris P L Lee et al.
International immunopharmacology, 9(5), 534-539 (2009-06-23)
Limited data are available on the mechanisms that constrain the function of regulatory populations of T cells. Prostaglandin E2 (PGE2) is an endogenous membrane phospholipid metabolite that has important immunomodulatory effects on T cell function. Our previous microarray data indicated
K J af Forselles et al.
British journal of pharmacology, 164(7), 1847-1856 (2011-05-21)
Studies of the role of the prostaglandin EP(2) receptor) have been limited by the availability of potent and selective antagonist tools. Here we describe the in vitro/in vivo pharmacological characterization of a novel EP(2) receptor antagonist, PF-04418948 (1-(4-fluorobenzoyl)-3-{[(6-methoxy-2-naphthyl)oxy]methyl} azetidine-3-carboxylic acid).
Structural features of subtype-selective EP receptor modulators
Markovivc T, et al.
Drug Discovery Today, 22(1), 57-71 (2017)
The vasopressin type 2 receptor and prostaglandin receptors EP2 and EP4 can increase aquaporin-2 plasma membrane targeting through a cAMP-independent pathway
Olesen ETB, et al.
American Journal of Physiology: Renal Physiology, 311(5), F935-F944 (2016)

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務